Viral Genetics Has Option Under Issued Key Patent for C... ( SAN MARINO Calif. May 21 /- Biotechno...)

Viral Genetics Has Option Under Issued Key Patent for Cancer Drug

Date:5/21/2009

SAN MARINO, Calif., May 21 /PRNewswire-FirstCall/ -- Biotechnology firm Viral Genetics, Inc. (Pink Sheets: VRAL), a company that discovers and develops drug compounds to treat cancer, Lyme Disease and HIV, has been issued a patent for novel cancer therapies. The patent protects cancer drugs that have been tested in pre-clinical research studies in mice. Issued on March 31, 2009, the U.S. Patent Number is: 7,510,710. Additional patents directed at generic classes of the drugs are still pending.

"This patent represents the first method for treating drug resistant cancer using metabolic disruption, an approach targeting the distinct cancer-specific metabolic activities that can distinguish cancer cells in general, and many drug resistant cancer types, in specific, from normal cells in normal tissues," said M. Karen Newell, PhD., tenured professor at the University of Colorado, Colorado Springs. Viral Genetics has certain exclusive licenses and options from the University of Colorado under previously filed patent rights, the work by Dr. M. Karen Newell and her group. Viral Genetics' licenses and options with the University are in return for certain obligations and fees.

"We are very excited that the Patent Office has recognized the significance of work we first pioneered over eight years ago. The scientific community is now coming to accept the approach, metabolic disruption, as an extremely promising method for helping cancer patients."

The new therapies use metabolic disruption as a treatment of cancers, including multi-drug resistant cancers. This process is accomplished by the administration of 2-deoxy-D-glucose to inhibit high rate glucose metabolism, characteristic of cancer cells. The administration of 2-deoxy-D-glucose can be used in combination with current, standard chemotherapeutics and/or in combination with etomoxir, an inhibitor of fatty acid oxidation. Drug resistant tumor
'/>"/>

0

GOOD

Page: 1 2 3 4
Related medicine news :

1. Pill box organizers increase HIV patients adherence and improve viral suppression
2. DNA damage response confers a barrier for viral tumorigenesis
3. Key Viral Change Could Help Bird Flu Spread
4. Antiviral Wont Improve Bells Palsy Outcome
5. Mayo Clinic Proceedings article explores possible link between obesity and viral infections
6. Is it pancreatitis in acute abdominal pain in acute viral hepatitis?
7. American Medical Association Clears Path for Adenoviral Conjunctivitis - Pink Eye - Detector
8. Antivirals reduce deaths from flu in hospitalized patients
9. MIGENIX Reports Preliminary Celgosivir Viral Kinetics Study
10. Antiretroviral Drugs May Prevent Vaginal Transmission of HIV
11. IPM Reaches Landmark Agreement with Pfizer to Develop FDA-Approved Antiretroviral Drug as Vaginal Microbicide

Post Your Comments:

Viral Genetics Has Option Under Issued Key Patent for C...( SAN MARINO Calif. May 21 /- Biotechno...),Health